5-HTP side effects: what is reported and how often
Futures Nutrition Editorial Team · 12 August 2026
5-HTP side effects: what is reported and how often
At the top of every list stand nausea, vomiting and diarrhoea — and they are not there by chance, but because they depend on the amount: the higher the daily amount, the more often they are reported. Behind them follow drowsiness and headache. Everything else you read about 5-HTP online comes either from individual case reports or from a forty-year-old story about a contaminated precursor.
What does not exist is the table most people are looking for: "common — affects 1 to 10 in 100 patients". That classification belongs to the package leaflet of an authorised medicine. A food supplement has no package leaflet and no authorisation procedure in which such frequencies would be collected. What exists is a list — and a handful of numbers from studies that worked with ten to seventy times what sits in a common tablet.
What an official label says
Canada's Natural and Non-prescription Health Products Directorate (NNHPD) lists 5-HTP in a product monograph dated 28 August 2024. It is currently the only official compilation that prescribes what has to appear on a pack — in Germany there is nothing comparable. Rendered in substance, it requires:
| Section on the pack | Wording in substance |
|---|---|
| While using | Gastrointestinal complaints may occur |
| While using | Caution when driving and operating machinery — drowsiness possible |
| Stop and consult | in case of hardening of the skin, pain or stiffness of muscles or joints, tremor, restlessness or confusion, increased heart rate |
| Do not use | in scleroderma; when taking antidepressants at the same time |
| Consult beforehand | with carbidopa or other serotonergic agents, in pregnancy and while breastfeeding |
| Age limit | adults from 18 years |
| Taking it | with food; start low and increase over two weeks |
Two things stand out. First: the only side effect named as regularly occurring concerns the digestive tract. Second: the list of warnings is markedly longer than the list of side effects — it mostly describes who should not take the product at all.
How common is "common"?
The most reliable set of figures comes from a study in 15 healthy men who received ascending amounts of 5-HTP (Smarius et al., Journal of Psychopharmacology 2008;22(4):426, PubMed 18308795). Nausea and vomiting were the most frequent adverse effects there, and the dropout rate rose with the amount:
| Amount of 5-HTP per dose | Study dropouts due to nausea and vomiting |
|---|---|
| 100 mg | 6.6 % |
| 300 mg | 45.5 % |
The authors' conclusion: above 100 mg, the frequent occurrence of nausea and vomiting limits usability. A review article on 5-HTP names the same threshold — vomiting and nausea have been reported from amounts above 100 mg (Maffei, International Journal of Molecular Sciences 2021;22(1):181).
These percentages are nevertheless not frequency figures in the sense of a package leaflet, for three reasons: it was 15 people, not an authorisation study. The participants additionally received carbidopa, an inhibitor that alters the conversion in the body. And what was measured was the dropout, not every complaint that occurred. How thin the evidence is overall is shown by a Cochrane review of 5-HTP and L-tryptophan: of 108 studies found, two met the quality criteria, 64 people in total (Shaw, Turner, Del Mar, Cochrane Database of Systematic Reviews 2002, CD003198). Reported there were dizziness, nausea and diarrhoea; what led to dropout was dizziness and upper abdominal pain.
Below roughly 50 mg per day — that is, the range food supplements move in — there are simply no systematically collected frequencies. That is not an all-clear but a gap: little studied means little known.
Why it hits the stomach first
5-HTP is not converted into serotonin only in the brain, but already before that — among other places in the intestinal wall. That is exactly where the gastrointestinal complaints come from: they are regarded as a consequence of the unintended conversion of 5-HTP into serotonin in the digestive tract (Turner, Loftis, Blackwell, Pharmacology & Therapeutics 2006;109(3):325, PubMed 16023217). By far the largest share of the body's own serotonin sits there anyway, not in the head.
From this follow the only two practical countermeasures the monograph gives: take it with food and start low. Why the meal costs nothing here is set out in 5-HTP: morning or evening, with or without food?. That the complaints coincide in time with the blood level — peak after one to two hours — can be read in 5-HTP: what to know about taking it.
Skin hardening, muscle pain, scleroderma: where that warning comes from
The most unusual point on the Canadian label has a historical background. In 1989 more than a thousand people in the USA fell ill with eosinophilia-myalgia syndrome, a disease with severe muscle pain and greatly elevated eosinophil blood cells. National surveillance counted 1,531 cases and 27 deaths up to 10 July 1990 (Swygert et al., JAMA 1990;264(13):1698). The cause was not 5-HTP but L-tryptophan from the production of a single Japanese manufacturer; after the recall in November 1989 new cases fell sharply.
5-HTP was then marketed as a replacement for the withdrawn L-tryptophan — and came into focus when similar contaminants turned up there too. An analysis group at the Mayo Clinic found three or more impurities of the so-called Peak X family in all eight commercial samples examined (Klarskov et al., Advances in Experimental Medicine and Biology 1999;467:461, PubMed 10721089).
The counterposition is just as clear: despite decades of worldwide use — with the exception of one unexplained case in Canada — no confirmed cases of 5-HTP poisoning are documented, and part of the specialist literature regards the Peak X findings as measurement artefacts at vanishingly small concentrations. The dispute is unresolved to this day. That is exactly why the warning is on the label, and exactly why the African black bean is listed in the EFSA compendium of botanicals, without a conclusive risk assessment of 5-HTP being available. How to recognise a cleanly declared extract is set out in Griffonia simplicifolia: the plant behind 5-HTP.
What is left of all this at 12.5 mg
Our 5-HTP + Vitamin B6 contains 12.5 mg of 5-HTP and 1.6 mg of vitamin B6 per tablet, with one tablet a day after a meal recommended. Both dose-dependent points therefore come out small: 12.5 mg lies a factor of eight below the amount at which nausea appears in the literature, and 1.6 mg of vitamin B6 corresponds to 13 per cent of the tolerable total intake that EFSA set in 2023 at 12 mg per day for adults (EFSA Journal 2023;21(5):8006).
The decisive harm with vitamin B6 is, incidentally, well documented and a different one from 5-HTP: nerve damage in the arms and legs with persistently high intake. EFSA used a value of 50 mg per day as the starting point for its derivation. That is why multiplying the number of tablets is not a good idea — the worked example is in 5-HTP dosage: how much is actually in there?.
For 5-HTP no health claim is authorised in the EU. For vitamin B6 the authorised claims read, in their official wording: Vitamin B6 contributes to normal functioning of the nervous system and Vitamin B6 contributes to normal psychological function (Regulation (EU) No 432/2012). Food supplements are not a substitute for a balanced and varied diet and a healthy lifestyle. The other articles and variants on the subject are in the 5-HTP category.
Who should not take it
The contraindications are clearer than the side effects. According to the Canadian monograph: not together with antidepressants, not in scleroderma. Consulting beforehand is provided for with carbidopa and with other serotonergic agents — these include cough remedies containing dextromethorphan, certain painkillers and certain anti-nausea medicines — as well as in pregnancy and while breastfeeding. For children and adolescents under 18 the substance is not intended there. Anyone who notices drowsiness should not drive.
Frequently asked questions
How quickly do the gastrointestinal complaints appear? In time they coincide with the blood level, which reaches its peak one to two hours after intake. In the studies they are mostly described as temporary and they diminish when the amount is increased slowly over two weeks instead of being taken in full straight away.
Why does my pack say none of this? Because a food supplement has no package leaflet. What is mandatory are ingredients, amounts, a consumption recommendation and a note not to exceed the recommended daily dose. The warning list quoted above comes from a Canadian labelling requirement, not from German food law.
Can I combine 5-HTP with melatonin? There are no studies on this combination — both act on the same metabolic pathway, and melatonin is formed in the body from serotonin. Without data all that remains is the consumption recommendation of the individual product, and stacking several serotonergic preparations belongs in a conversation with a doctor. Unlike 5-HTP, Melatonin 2 mg has an authorised claim: Melatonin contributes to the reduction of time taken to fall asleep. The beneficial effect is obtained with the consumption of 1 mg of melatonin close to bedtime.
Are side effects a sign that it is working? No. Nausea arises in the digestive tract and says nothing about what else is happening in the body. For 5-HTP no effect is authorised in the EU anyway; the applications on mood, attention and satiety were rejected by EFSA for lack of evidence (EFSA Journal 2009;7(10):1273 and 2011;9(6):2198).
Sources: Health Canada / NNHPD, monograph "5-HTP", as of 28 August 2024 · Smarius et al., Journal of Psychopharmacology 2008;22(4):426 (PubMed 18308795) · Shaw, Turner, Del Mar, Cochrane Database of Systematic Reviews 2002, CD003198 · Turner, Loftis, Blackwell, Pharmacology & Therapeutics 2006;109(3):325 (PubMed 16023217) · Swygert et al., JAMA 1990;264(13):1698 (PubMed 2398610) · Klarskov et al., Advances in Experimental Medicine and Biology 1999;467:461 (PubMed 10721089) · Maffei, International Journal of Molecular Sciences 2021;22(1):181 · EFSA, Tolerable upper intake level for vitamin B6, EFSA Journal 2023;21(5):8006 · EFSA compendium of botanicals · Regulation (EU) No 432/2012.
